ホーム>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Aristeromycin

Aristeromycin

カタログ番号GC35387

アデノシン類似体であるアリステロマイシンは、抗生物質であり、強力な S-アデノシルホモシステイン加水分解酵素 (AHCY) 阻害剤です 。

Products are for research use only. Not for human use. We do not sell to patients.

Aristeromycin 化学構造

Cas No.: 19186-33-5

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$446.00
在庫あり
1mg
$184.00
在庫あり
5mg
$405.00
在庫あり
10mg
$720.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Aristeromycin, an adenosine analog, is an antibiotic and a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor[1][2]. S-adenosylhomocysteine hydrolase[1]

The IC50 value of Aristeromycin against AHCY is 38.5 nM at 50 μM S-adenosylhomocysteine (SAH) (approximately equal to the Km: 48 μM), but 271 nM at 1000 µM SAH (20× Km). With 60 min of preincubation, the mean IC50 value of Aristeromycin at 50 μM SAH is 12.7 nM[1].Aristeromycin has IC50 values of 3.2 μM for LNCaP-FGC cell growth and 0.88 μM for LNCaP-hr cell growth[1].At least in part, Aristeromycin can regulate oncogenic EZH2 expression by inducing miR-26a[1].

[1]. Uchiyama N, et al. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a. Eur J Pharmacol. 2017 Oct 5;812:138-146. [2]. Ishikura T, et al. Inhibition of S-adenosylhomocysteine hydrolase by purine nucleoside analogues. Nucleic Acids Symp Ser. 1983;(12):119-22.

レビュー

Review for Aristeromycin

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Aristeromycin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.